Signature Estate & Investment Advisors LLC Purchases Shares of 65,754 Boston Scientific Corporation $BSX

Key Points

• Signature Estate & Investment Advisors LLC acquired 65,754 shares of Boston Scientific Corporation, valued at approximately $7.06 million, in the second quarter of this year.
• A significant percentage, 89.07%, of Boston Scientific's stock is currently owned by institutional investors, with various hedge funds increasing their holdings.
• Boston Scientific's stock has a current average rating of "Buy" from analysts, with a consensus target price set at $120.71.

Signature Estate & Investment Advisors LLC purchased a new stake in Boston Scientific Corporation (NYSE:BSX - Free Report) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 65,754 shares of the medical equipment provider's stock, valued at approximately $7,063,000.

A number of other hedge funds have also recently bought and sold shares of BSX. Vanguard Group Inc. grew its stake in Boston Scientific by 1.3% in the first quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider's stock valued at $13,577,311,000 after purchasing an additional 1,697,945 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in Boston Scientific by 18.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 10,610,487 shares of the medical equipment provider's stock valued at $1,070,387,000 after purchasing an additional 1,664,108 shares in the last quarter. Swedbank AB grew its stake in Boston Scientific by 114.5% in the second quarter. Swedbank AB now owns 2,819,249 shares of the medical equipment provider's stock valued at $302,816,000 after purchasing an additional 1,505,019 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in Boston Scientific by 10.8% in the first quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider's stock valued at $1,426,779,000 after purchasing an additional 1,383,524 shares in the last quarter. Finally, Ninety One UK Ltd grew its stake in Boston Scientific by 33.5% in the second quarter. Ninety One UK Ltd now owns 5,146,218 shares of the medical equipment provider's stock valued at $552,755,000 after purchasing an additional 1,290,414 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on BSX. Truist Financial raised their price objective on Boston Scientific from $125.00 to $129.00 and gave the company a "buy" rating in a research report on Wednesday, October 1st. Barclays raised their price objective on Boston Scientific from $133.00 to $136.00 and gave the company an "overweight" rating in a research report on Thursday, October 2nd. Wells Fargo & Company raised their price objective on Boston Scientific from $118.00 to $124.00 and gave the company an "overweight" rating in a research report on Thursday, July 24th. Erste Group Bank cut Boston Scientific from a "buy" rating to a "hold" rating in a research report on Friday, October 3rd. Finally, Jefferies Financial Group reaffirmed a "hold" rating on shares of Boston Scientific in a research report on Monday, July 21st. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and two have assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $120.71.

Boston Scientific Stock Performance

NYSE:BSX opened at $99.20 on Friday. The stock has a market cap of $146.99 billion, a P/E ratio of 59.05, a PEG ratio of 2.39 and a beta of 0.61. The stock has a 50 day simple moving average of $101.29 and a 200 day simple moving average of $101.75. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. Boston Scientific Corporation has a 1-year low of $80.64 and a 1-year high of $109.50.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.03. The business had revenue of $5.06 billion during the quarter, compared to analysts' expectations of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The firm's revenue for the quarter was up 22.8% compared to the same quarter last year. During the same period last year, the firm posted $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Research analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Insider Buying and Selling

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the completion of the transaction, the executive vice president directly owned 23,600 shares of the company's stock, valued at $2,469,268. The trade was a 42.32% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Edward J. Ludwig sold 4,000 shares of Boston Scientific stock in a transaction on Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the completion of the transaction, the director directly owned 18,479 shares of the company's stock, valued at $1,959,328.37. This represents a 17.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 174,214 shares of company stock valued at $17,972,457 over the last 90 days. 0.50% of the stock is currently owned by insiders.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.